PYCR1
protein-codingpyrroline-5-carboxylate reductase 1
Gene summary
This gene encodes an enzyme that catalyzes the NAD(P)H-dependent conversion of pyrroline-5-carboxylate to proline. This enzyme may also play a physiologic role in the generation of NADP(+) in some cell types. The protein forms a homopolymer and localizes to the mitochondrion. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~10.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0013755
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0013755
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0013051
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0013051
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0009271
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0013051
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0013051
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0013051
Submitter: ClinGen
PYCR1 was first reported in relation to autosomal recessive cutis laxa in 2009 (Guernsey DL, et al., 2009, PMID: 19576563; Reversade B, et al., 2009, PMID: 19648921). At least 40 unique variants (e.g. missense, in-frame indel, nonsense, frameshift, etc.) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Variants in this gene have been reported in at least 13 probands in the two initial publications. Variants in this gene segregated with disease in two additional family members (Guernsey DL, et al., 2009, PMID: 19576563). More evidence is available in the literature, but the maximum score for genetic evidence has been reached. This gene-disease relationship is supported by the function of PYCR1 in proline metabolism, its expression in bone and skin, and animal models in Xenopus and Zebrafish with partial recapitulation of disease. In summary, PYCR1 is definitively associated with autosomal recessive cutis laxa. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.
Inheritance Pattern: AR
Disease ID:MONDO:0013755
Submitter: G2P
Inheritance Pattern: AR
Disease ID:MONDO:0013755
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0013051
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Dermatologic; Musculoskeletal; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PYCR1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_006907.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 94 | 2 | 96 | |||
| missense | 3 | 19 | 106 | 7 | 1 | 136 |
| nonsense | 4 | 1 | 5 | |||
| start loss | 0 | |||||
| frameshift | 9 | 9 | 18 | |||
| splice donor/acceptor (+/-2bp) | 4 | 8 | 2 | 14 | ||
| Total | 16 | 40 | 109 | 101 | 3 | 269 |
Highest pathogenic variant AF is 0.00014014322
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_008838.2 | 7 | MANE Select | |
| Ensembl | ENSP00000328858.8 | 7 | MANE Select | |
| RefSeq | NP_001269208.1 | 6 | Standard | |
| RefSeq | NP_001269209.1 | 7 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| pycr1b | Danio rerio | Structure: post-vent region Quality: increased curvature abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Arginine and proline metabolism - Homo sapiens (human)
- Amino Acid metabolism
- Urea cycle and metabolism of amino groups
- Metabolism of amino acids and derivatives
- Metabolism
Biological Process
- proline biosynthetic process
- cellular amino acid biosynthetic process
- cellular response to oxidative stress
- regulation of mitochondrial membrane potential
- oxidation-reduction process
Molecular Function
- pyrroline-5-carboxylate reductase activity
- protein binding
- identical protein binding
Cellular Component
- mitochondrion
- mitochondrial matrix
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000329875
- Coding exons
- 7
- Length
- 10029
- Individuals with no LoFs
- 125475
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 31
- Defined
- 125506
- p
- 0.000124
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.173 | 187 | 194 | 0.965 | 0.0000130 | 2039 |
| Missense (PolyPhen) | 49 | 65.038 | 0.75341 | 662 | ||
| Synonymous | 0.170 | 81 | 83.0 | 0.976 | 0.00000613 | 684 |
| Loss of Function | 0.988 | 7 | 10.4 | 0.670 | 5.54e-7 | 118 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00012 | 0.00012 | rare |
| Latino/Admixed American | 0.000029 | 0.000029 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00060 | 0.00060 | rare |
| Finnish | 0.000048 | 0.000046 | rare |
| European (Non-Finnish) | 0.000055 | 0.000053 | rare |
| South Asian | 0.00033 | 0.00033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Housekeeping enzyme that catalyzes the last step in proline biosynthesis. Can utilize both NAD and NADP, but has higher affinity for NAD. Involved in the cellular response to oxidative stress. {ECO:0000269|PubMed:16730026, ECO:0000269|PubMed:19648921}.;
- Disease
- DISEASE: Cutis laxa, autosomal recessive, 2B (ARCL2B) [MIM:612940]: A disorder characterized by an excessive congenital skin wrinkling, a large fontanelle with delayed closure, a typical facial appearance with downslanting palpebral fissures, a general connective tissue weakness, and varying degrees of growth and developmental delay and neurological abnormalities. Patients do not manifest metabolic abnormalities. {ECO:0000269|PubMed:19576563, ECO:0000269|PubMed:19648921}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cutis laxa, autosomal recessive, 3B (ARCL3B) [MIM:614438]: A disorder characterized by an aged appearance with distinctive facial features, sparse hair, ophthalmologic abnormalities, intrauterine growth retardation, and cutis laxa. {ECO:0000269|PubMed:19648921, ECO:0000269|PubMed:22052856}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.263
Intolerance Scores
- LoFtool
- 0.449
- RVIS EVS
- -0.53
- RVIS percentile EVS
- 20.7
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.996
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |